Download PDF
Drug Res (Stuttg) 2016; 66(06): 330-336
DOI: 10.1055/s-0035-1569447
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study

K. Razavi-Azarkhiavi
1   Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
A. H. Jafarian
2   Cancer Molecular Research Center, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
,
K. Abnous
3   Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
B. M. Razavi
1   Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
K. Shirani
1   Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
M. Zeinali
1   Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4   Social Security Organization, Mashhad, Islamic Republic of Iran
,
M. R. Jaafari
5   Biotechnology Research Center, Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
G. Karimi
6   Medical Toxicology Research Center and Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran
› Author Affiliations
Further Information

Publication History

received 30 December 2015

accepted 24 February 2016

Publication Date:
29 March 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Over the past several years, the considerable attention has been progressively given to liposomal formulations of anthracyclines. SinaDoxosome® (Exir Nano Sina Company, Iran) is a pegylated liposomal doxorubicin (DOX) which approved by Food and Drug Administration of IRAN for treatment of some types of cancer. The aim of this study was to compare the biodistribution, efficacy, cardiotoxicity and hepatotoxicity of SinaDoxosome® with Caelyx® in mice bearing C-26 colon carcinoma.

Methods and results: Mice tumor size evaluation during the experimental period (28 days) showed comparable therapeutic efficacy of nano-formulations. The biodistribution studies showed no significant difference in DOX tissue concentration between Caelyx® and SinaDoxosome®. DOX induced-ECG changes were not detected in nano-formulations. No significant alteration was found in biochemical indexes of myocardial injury in mice exposed to nano-formulations in comparison with control mice. The tissue oxidative parameters such as lipid peroxidation, glutathione, catalase and superoxide dismutase was significantly changed as the results of free DOX treatment. However, the oxidative status of Caelyx® and SinaDoxosome® treated animals did not showed any changes. The experiment also revealed that apoptotic pathway was not activated in the heart of mice exposed to nano-formulations.

Conclusions: Although this investigation showed that Caelyx® and SinaDoxosome® are similar in terms of biodistribution, efficacy and toxicity, appropriate clinical evaluations in patients should be considered.

Key words

caelyx® - sinadoxosome® - biodistribution - cardiotoxicity - oxidative stress
 

  • References

  • 1 Rafiyath SM, Rasul M, Lee B et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012; 1: 10
    CrossrefPubMedGoogle Scholar
  • 2 Bonadonna G, Monfardini S, De Lena M et al. and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970; 30: 2572-2582
    PubMedGoogle Scholar
  • 3 Pisano C, Cecere SC, Di Napoli M et al. Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J drug deliv 2013; 2013: 898146
    PubMedGoogle Scholar
  • 4 Pointon AV, Walker TM, Phillips KM et al. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 2010; 5: e12733
    CrossrefPubMedGoogle Scholar
  • 5 Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat med 2012; 18: 1639-1642
    CrossrefPubMedGoogle Scholar
  • 6 Arozal W, Suyatna FD, Juniantito V et al. The Effects of Mangiferin (Mangifera indica L) in Doxorubicin-induced Cardiotoxicity in Rats. Drug Res 2015; 65: 574-580
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Neilan TG, Blake SL, Ichinose F et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007; 116: 506-514
    CrossrefPubMedGoogle Scholar
  • 8 Ding J, Shi F, Li D et al. Correction: Enhanced endocytosis of acid-sensitive doxorubicin derivatives with intelligent nanogel for improved security and efficacy. Biomater Sci 2013; 1: 633-646
    CrossrefPubMedGoogle Scholar
  • 9 Xu W, Ding J, Xiao C et al. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. Biomaterials 2015; 54: 72-86
    CrossrefPubMedGoogle Scholar
  • 10 Yuan MQ, Zhu F, Lou JY et al. The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer. Drug Res 2014; 64: 195-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Wang X, Song L, Li N et al. Pharmacokinetics and biodistribution study of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs by liquid chromatography-tandem mass spectrometry. Drug Res 2013; 63: 603-606
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Wang J, Xu W, Guo H et al. Selective intracellular drug delivery from pH-responsive polyion complex micelle for enhanced malignancy suppression in vivo. Colloids Surf B 2015; 135: 283-290
    CrossrefPubMedGoogle Scholar
  • 13 Ding J, Li C, Zhang Y et al. Chirality-mediated polypeptide micelles for regulated drug delivery. Acta Biomater 2015; 11: 346-355
    CrossrefPubMedGoogle Scholar
  • 14 Swenson C, Perkins W, Roberts P et al. Liposome technology and the development of Myocet™(liposomal doxorubicin citrate). The Breast 2001; 10: 1-7
    PubMedGoogle Scholar
  • 15 Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63: 136-151
    CrossrefPubMedGoogle Scholar
  • 16 Caraglia M, De Rosa G, Salzano G et al. Nanotech revolution for the anti-cancer drug delivery through blood-brain-barrier. Curr Cancer Drug Targets 2012; 12: 186-196
    CrossrefPubMedGoogle Scholar
  • 17 Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997; 11: 11-20
    PubMedGoogle Scholar
  • 18 O’brien M, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann oncol 2004; 15: 440-449
    CrossrefPubMedGoogle Scholar
  • 19 Safra T, Muggia F, Jeffers S et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 . Ann oncol 2000; 11: 1029-1033
    CrossrefPubMedGoogle Scholar
  • 20 Huang Z, Jaafari MR, Szoka FC. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem 2009; 121: 4210-4213
    CrossrefPubMedGoogle Scholar
  • 21 Hanafi-Bojd MY, Jaafari MR, Ramezanian N et al. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm 2015; 89: 248-258
    CrossrefPubMedGoogle Scholar
  • 22 Amin M, Badiee A, Jaafari MR. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J pharm 2013; 458: 324-333
    CrossrefPubMedGoogle Scholar
  • 23 Buege JA. Microsomal lipid peroxidation. Method Enzymol 1978; 52: 302-310
    PubMedGoogle Scholar
  • 24 Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205
    CrossrefPubMedGoogle Scholar
  • 25 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 26 Wibroe PP, Ahmadvand D, Oghabian MA et al. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. J Controlled Release 2016; 221: 1-8
    CrossrefPubMedGoogle Scholar
  • 27 Tomonari M, To H, Nishida M et al. Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity. J Pharmacol Sci 2011; 115: 336-345
    CrossrefPubMedGoogle Scholar
  • 28 den Hartog GJ, Haenen GR, Boven E et al. Lecithinized copper, zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 2004; 194: 180-188
    CrossrefPubMedGoogle Scholar
  • 29 Uma Mahesh B, Shrivastava S, Kuncha M et al. Ethanolic extract of Boswellia ovalifoliolata bark and leaf attenuates doxorubicin-induced cardiotoxicity in mice. Environ Toxicol Pharmacol 2013; 36: 840-849
    CrossrefPubMedGoogle Scholar
  • 30 Jiang B, Zhang L, Li M et al. Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem Toxicol 2008; 46: 1510-1515
    CrossrefPubMedGoogle Scholar
  • 31 Chen CT, Wang ZH, Hsu CC et al. In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity. Nutrients 2015; 7: 4938-4954
    CrossrefPubMedGoogle Scholar
  • 32 Lien CY, Chuang TY, Hsu CH et al. Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis. Onco Targets Ther 2015; 8: 1193-1210
    PubMedGoogle Scholar
  • 33 Meeran N, Fizur M, Stanely Mainzen Prince P. Protective effects of thymol on altered plasma lipid peroxidation and nonenzymic antioxidants in isoproterenol-induced myocardial infarcted rats. J Biochem Mol Toxicol 2012; 26: 368-373
    CrossrefPubMedGoogle Scholar
  • 34 Wang Y, Hirai K, Ashraf M. Activation of mitochondrial ATP-sensitive K+ channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 1999; 85: 731-741
    CrossrefPubMedGoogle Scholar
  • 35 Hassani S, Sepand M, Jafari A et al. Protective effects of curcumin and vitamin E against chlorpyrifos-induced lung oxidative damage. Hum Exp Toxicol 2014; 0960327114550888
    PubMedGoogle Scholar
  • 36 Demirci S, Kutluhan S, Nazıroğlu M et al. Effects of selenium and topiramate on cytosolic Ca2+ influx and oxidative stress in neuronal PC12 cells. Neurochem Res 2013; 38: 90-97
    CrossrefPubMedGoogle Scholar
  • 37 McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 2013; 5: a008656
    Google Scholar
  • 38 Xu X, Zhang Y, Qu D et al. Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J Exp Clin Cancer Res 2011; 30: 33
    CrossrefPubMedGoogle Scholar
  • 39 Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002; 21: 3727-3738
    CrossrefPubMedGoogle Scholar
  • 40 Emi M, Kim R, Tanabe K et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7: 940-952
    CrossrefPubMedGoogle Scholar